Tilray projects $68M-$75M adjusted EBITDA in fiscal 2027 as it targets margin expansion
View original at seekingalpha.comWhat we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
4Q organic growth, excluding BrewDog, was down 17%.
60% confidenceTilray is not a one-trick pony and is not waiting on U.S. cannabis rescheduling/legalization, which is not projected in its numbers.
60% confidenceInternational cannabis revenue was impacted by approximately $21.1 million of price compression, which largely flows through to gross profit and the bottom line.
60% confidenceTilray has plenty of cannabis supply and could be one of the lowest cost producers given its scale and size.
60% confidenceAdjusted EBITDA increased 11% to $61.1 million, impacted by approximately $2.3 million in unanticipated fuel surcharges.
60% confidenceOver time, Tilray aims to be a 15% to 18% EBITDA margin business.
60% confidenceTilray reduced debt by approximately $60 million, ending the year with net debt of less than $1 million; since April it raised $87 million of gross proceeds via ATM at an average price of $6.77 per share.
60% confidenceBeginning January 1, 2027, Tilray will brew, market and sell Carlsberg, Carlsberg Elephant 1664, and Kronenbourg 1664 Blanc across the U.S.
60% confidenceThe 4Q beverage decline excluding BrewDog was self-inflicted from skew rationalization and exiting unprofitable businesses; Shock Top and Carlsberg will be the two national brands, with the rest regional.
60% confidenceTilray would consider entering big U.S. states under a state-silo model where opportunities exist, but would need to weigh policy durability.
60% confidenceTilray ended fiscal 2026 with approximately $235 million in cash and marketable securities and near-breakeven net debt, plus nearly $700 million of operating assets.
60% confidenceThe integration and optimization of acquired beverage brands has taken longer than expected amid broader category headwinds.
60% confidenceIn the prior quarter, management reaffirmed fiscal 2026 adjusted EBITDA guidance of $62 million to $72 million.
60% confidenceThe Canada adult-use volume/pricing shift was 90% driven by mix, with a small positive pricing contribution offset by international shipment declines and deprioritization of wholesale.
60% confidenceInternational cannabis growth is sustained by having supply, improved speed of permits, and demand growth, despite major European price compression this year.
60% confidenceNet loss improved significantly to $105.2 million or $1.09 per share; adjusted net income improved 87% to $12.2 million or $0.11 per share.
60% confidenceTilray is a diversified global consumer products and pharmaceutical distribution company with leadership positions across cannabis, beverage, hospitality and wellness.
60% confidenceFiscal 2026 proves Tilray Brands is more than the company many people think it is.
60% confidenceNet revenue increased 11% in fiscal 2026 to a record $915.5 million, and net cannabis revenue increased 8% to $268.3 million.
60% confidenceFull vertical integration on the medical side ensures consistent grow, quality, and avoids buying in a spot market; Tilray has doctors and pharmacy staff.
60% confidenceFiscal 2026 delivered record revenue of over $915 million on an annualized pro forma basis and record adjusted EBITDA of $61.1 million ($63.4 million excluding fuel surcharges).
60% confidenceTilray is providing fiscal 2027 guidance of adjusted EBITDA between $68 and $75 million, a double-digit increase from fiscal 2026.
60% confidenceNobody has figured out U.S. cannabis rescheduling yet, and Tilray will be disciplined about M&A rather than jumping in.
60% confidenceEBITDA seasonality has quarters 1, 2 and 3 being roughly half the year combined, with quarter 4 being the other half.
60% confidenceVeterans Affairs reimbursement changes are calculated to have a $4 million a year impact on revenue in fiscal 2027.
60% confidenceCC Pharma's margin improvement reflects portfolio management, and Tilray is working toward compounding and a direct-to-consumer model in Germany.
60% confidenceTilray entered fiscal 2027 with priorities to expand margins, improve efficiency, accelerate innovation, and convert scale into stronger earnings power.
60% confidenceFourth quarter total net revenue increased 25% to $281.7 million and adjusted EBITDA increased 15% to a record $31.9 million.
60% confidenceTilray acquired an over $200 million annual revenue business for approximately $54 million and invested nearly $50 million of additional working capital.
60% confidence